Rationale for annual screening mammography for women ages 40-49 years

Stephen A. Feig, Daniel B. Kopans, Edward A. Sickles, Valerie Jackson, Barbara Monsees

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Proof of the benefit for mammographic screening of women ages 40-49 years is now available. Randomized controlled trials (RCTs) conducted in Gothenburg and Malmo, Sweden have shown statistically significant breast cancer mortality reductions of 36% and 45%, respectively. A meta-analysis of all five Swedish trials has found a statistically significant mortality reduction of 29% for women in this age group. Substantially greater reductions in mortality would likely have resulted if women in these trials had been screened annually. Because the benefits are substantial, and the risks from screening are relatively small and acceptable, screening mammography beginning at age 40 is now recommended by the American Cancer Society, as well as the National Cancer Institute.

Original languageEnglish
Pages (from-to)13-21
Number of pages9
JournalBreast Disease
Volume10
Issue number3-4
StatePublished - Aug 1998

Fingerprint

Mammography
Mortality
National Cancer Institute (U.S.)
Sweden
Meta-Analysis
Randomized Controlled Trials
Age Groups
Breast Neoplasms

ASJC Scopus subject areas

  • Surgery

Cite this

Feig, S. A., Kopans, D. B., Sickles, E. A., Jackson, V., & Monsees, B. (1998). Rationale for annual screening mammography for women ages 40-49 years. Breast Disease, 10(3-4), 13-21.

Rationale for annual screening mammography for women ages 40-49 years. / Feig, Stephen A.; Kopans, Daniel B.; Sickles, Edward A.; Jackson, Valerie; Monsees, Barbara.

In: Breast Disease, Vol. 10, No. 3-4, 08.1998, p. 13-21.

Research output: Contribution to journalArticle

Feig, SA, Kopans, DB, Sickles, EA, Jackson, V & Monsees, B 1998, 'Rationale for annual screening mammography for women ages 40-49 years', Breast Disease, vol. 10, no. 3-4, pp. 13-21.
Feig SA, Kopans DB, Sickles EA, Jackson V, Monsees B. Rationale for annual screening mammography for women ages 40-49 years. Breast Disease. 1998 Aug;10(3-4):13-21.
Feig, Stephen A. ; Kopans, Daniel B. ; Sickles, Edward A. ; Jackson, Valerie ; Monsees, Barbara. / Rationale for annual screening mammography for women ages 40-49 years. In: Breast Disease. 1998 ; Vol. 10, No. 3-4. pp. 13-21.
@article{8ad4580ca8ac4bf4821ac37df956807b,
title = "Rationale for annual screening mammography for women ages 40-49 years",
abstract = "Proof of the benefit for mammographic screening of women ages 40-49 years is now available. Randomized controlled trials (RCTs) conducted in Gothenburg and Malmo, Sweden have shown statistically significant breast cancer mortality reductions of 36{\%} and 45{\%}, respectively. A meta-analysis of all five Swedish trials has found a statistically significant mortality reduction of 29{\%} for women in this age group. Substantially greater reductions in mortality would likely have resulted if women in these trials had been screened annually. Because the benefits are substantial, and the risks from screening are relatively small and acceptable, screening mammography beginning at age 40 is now recommended by the American Cancer Society, as well as the National Cancer Institute.",
author = "Feig, {Stephen A.} and Kopans, {Daniel B.} and Sickles, {Edward A.} and Valerie Jackson and Barbara Monsees",
year = "1998",
month = "8",
language = "English",
volume = "10",
pages = "13--21",
journal = "Breast Disease",
issn = "0888-6008",
publisher = "IOS Press",
number = "3-4",

}

TY - JOUR

T1 - Rationale for annual screening mammography for women ages 40-49 years

AU - Feig, Stephen A.

AU - Kopans, Daniel B.

AU - Sickles, Edward A.

AU - Jackson, Valerie

AU - Monsees, Barbara

PY - 1998/8

Y1 - 1998/8

N2 - Proof of the benefit for mammographic screening of women ages 40-49 years is now available. Randomized controlled trials (RCTs) conducted in Gothenburg and Malmo, Sweden have shown statistically significant breast cancer mortality reductions of 36% and 45%, respectively. A meta-analysis of all five Swedish trials has found a statistically significant mortality reduction of 29% for women in this age group. Substantially greater reductions in mortality would likely have resulted if women in these trials had been screened annually. Because the benefits are substantial, and the risks from screening are relatively small and acceptable, screening mammography beginning at age 40 is now recommended by the American Cancer Society, as well as the National Cancer Institute.

AB - Proof of the benefit for mammographic screening of women ages 40-49 years is now available. Randomized controlled trials (RCTs) conducted in Gothenburg and Malmo, Sweden have shown statistically significant breast cancer mortality reductions of 36% and 45%, respectively. A meta-analysis of all five Swedish trials has found a statistically significant mortality reduction of 29% for women in this age group. Substantially greater reductions in mortality would likely have resulted if women in these trials had been screened annually. Because the benefits are substantial, and the risks from screening are relatively small and acceptable, screening mammography beginning at age 40 is now recommended by the American Cancer Society, as well as the National Cancer Institute.

UR - http://www.scopus.com/inward/record.url?scp=0031714416&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031714416&partnerID=8YFLogxK

M3 - Article

C2 - 15687560

AN - SCOPUS:0031714416

VL - 10

SP - 13

EP - 21

JO - Breast Disease

JF - Breast Disease

SN - 0888-6008

IS - 3-4

ER -